The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

• Status: Terminated
• Trial end date: 2020-01-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Central Florida
• Treatments: abobotulinumtoxinA; Botulinum Toxins, Type A; onabotulinumtoxinA; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Male or female adult between 18 and 80 years of age

• Must have health insurance

• Must have a current diagnosis of Raynaud's phenomenon

Exclusion Criteria:

• Allergy to abobotulinum toxin A or its components

• Diagnosis of myasthenia gravis

• Previously received abobotulinum toxin vaccine

• Previously undergone upper extremity vascular surgery (including surgical sympathectomy)

• Currently receiving aminoglycoside antibiotics

• Received abobotulinum toxin A treatment in either hand in the past 6 months

• Pregnant women

• Women currently breastfeeding

• Current tobacco smoker (use in the past 12 months)

• Unable to read and speak English

• Adults unable to consent

• Individuals who are not yet adults (infants, children, teenagers)

• Prisoners